Licensing agreement with Gliknik


Our client Pfizer Inc. entered into an exclusive worldwide licensing agreement with Gliknik Inc., a privately held biopharmaceutical company, for GL-2045, Gliknik’s recombinant stradomer™, a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin.

Under the terms of the agreement, Pfizer received an exclusive worldwide license to GL-2045 for all therapeutic indications. Gliknik received an upfront payment of $25 million and was eligible to receive development, regulatory, and commercial milestone payments. Gliknik was also eligible to receive tiered, double-digit royalties on net sales of any products that are commercialized pursuant to the licensing agreement.

Email Disclaimer